Most Active Biotech Investors in Basel 2026

6 firms writing Biotech checks in Basel, led by Google Ventures, Novartis Venture Fund, Omega Funds — ranked by verified deal count with the companies behind.

Biotech in Basel accounts for 3 tracked companies with verified cap-table data, 3 of which disclose round sizes totalling $469M. The median disclosed raise is $171M, and the largest is Windward Bio at $200M, ahead of Noema Pharma ($171M) and Rhygaze ($97M).

The names that recur most often on these biotech cap tables are OrbiMed (1 company), Novo Holdings (1 company), Blue Owl Healthcare Opportunities (1 company), SR One (1 company), Omega Funds (1 company), RTW Investments (1 company). By latest disclosed round, the market skews Series A (2), Series B (1).

Companies tracked: 3
Disclosed funding total: $469M across 3 companies
Median disclosed raise: $171M
Largest raise: Windward Bio — $200M
Stage mix: Series A 2 · Series B 1
Most recent dated round: 2026-05-04

Best funded Biotech in Basel companies

Windward Bio — $200M (latest: Series A)
Noema Pharma — $171M (latest: Series B)
Rhygaze — $97M (latest: Series A)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library